当前位置:首页 - 行情中心 - 锦波生物(920982) - 财务分析 - 利润表

锦波生物

(920982)

  

流通市值:68.44亿  总市值:141.99亿
流通股本:5546.51万   总股本:1.15亿

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入771,082,522.84375,372,555.961,595,372,919.281,295,732,666.6
  营业收入771,082,522.84375,372,555.961,595,372,919.281,295,732,666.6
二、营业总成本445,677,659.51218,368,822.25825,957,509.81620,389,060.82
  营业成本117,961,559.4656,981,893.11172,119,657.78119,180,681.79
  税金及附加13,238,907.166,655,245.3427,271,605.121,376,768.42
  销售费用181,723,004.5387,892,692.94375,946,448.97289,442,165.63
  管理费用83,007,323.1141,347,360.26136,520,971.34112,971,706.25
  研发费用42,855,90522,470,678.12106,011,667.3571,261,580.37
  财务费用6,890,960.253,020,952.488,087,159.276,156,158.36
  其中:利息费用5,625,837.322,428,335.957,375,624.825,680,008.72
  其中:利息收入342,293.02203,061.63855,599.4622,359.06
三、其他经营收益
  加:投资收益4,822,721.422,052,393.986,176,174.864,889,164.88
  资产减值损失(新)-1,216,013.93-364,911.98-23,085,134.39-11,561,283.52
  信用减值损失(新)-5,235,420.49-1,158,924.4-8,027,981.08-7,805,119.56
  其他收益12,199,300.669,534,547.2623,808,685.3610,182,080.7
四、营业利润335,975,450.99167,066,838.57768,287,154.22671,048,448.28
  加:营业外收入241,208.3736,551.13639,821.45111,490.62
  减:营业外支出806,687.04138,703.188,566,680.854,463,477.39
五、利润总额335,409,972.32166,964,686.52760,360,294.82666,696,461.51
  减:所得税费用53,250,637.5426,005,600.83114,649,788.24102,056,444.36
六、净利润282,159,334.78140,959,085.69645,710,506.58564,640,017.15
(一)按经营持续性分类
  持续经营净利润282,159,334.78140,959,085.69645,710,506.58564,640,017.15
(二)按所有权归属分类
  归属于母公司股东的净利润281,484,712.49140,454,965.87652,128,968.1568,273,346.52
  少数股东损益674,622.29504,119.82-6,418,461.52-3,633,329.37
  扣除非经常损益后的净利润268,049,768.55131,092,491.15635,506,016.42559,736,614.17
七、每股收益
  (一)基本每股收益2.451.225.674.94
  (二)稀释每股收益2.451.225.674.94
九、综合收益总额282,159,334.78140,959,085.69645,710,506.58564,640,017.15
  归属于母公司股东的综合收益总额281,484,712.49140,454,965.87652,128,968.1568,273,346.52
  归属于少数股东的综合收益总额674,622.29504,119.82-6,418,461.52-3,633,329.37
公告日期2026-08-252026-04-292026-04-292025-10-29
审计意见(境内)标准无保留意见
TOP↑